Gemcitabine twice weekly as a radiosensitiser for the treatment of brain metastases in patients with carcinoma: a phase I study - Wikidata - awgldk - TriplyDB

Gemcitabine twice weekly as a radiosensitiser for the treatment of brain metastases in patients with carcinoma: a phase I study

Gemcitabine twice weekly as a radiosensitiser for the treatment of brain metastases in patients with carcinoma: a phase I study

http://www.wikidata.org/entity/Q33365043

about

The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines Regression of experimental NIS-expressing breast cancer brain metastases in response to radioiodide/gemcitabine dual therapy Towards tailored therapy of glioblastoma multiforme.Use of Systemic Therapy Concurrent With Cranial Radiotherapy for Cerebral Metastases of Solid Tumors.Brain metastases from colorectal cancer: characteristics and management.Dose escalation in patients receiving whole-brain radiotherapy for brain metastases from colorectal cancer.Circadian physiology is a toxicity target of the anticancer drug gemcitabine in mice.

P2860

Q33245149-68DED98E-9422-4D50-B1CC-EF7B407AAFC9 Q37688145-458779AB-15AA-4B0A-AF84-3D466CB7CB8F Q37908815-CC40F120-50AD-4730-AD01-40E5E07E85A3 Q38975455-F0A6E7B3-6522-4808-9A45-9CA5A8E46AA3 Q39421313-0CABA351-2B35-4B40-B5A7-1AAF798CEF5D Q48323151-EA5C3475-9ACD-43C1-94E2-4B49CF0D9100 Q52578529-88FF4D15-616D-407A-A6A3-A91576DF0424

P2860

Gemcitabine twice weekly as a radiosensitiser for the treatment of brain metastases in patients with carcinoma: a phase I study

http://www.wikidata.org/entity/Q33365043

description

2005 nî lūn-bûn

@nan

2005 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի մարտին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Gemcitabine twice weekly as a ...... ith carcinoma: a phase I study

@ast

Gemcitabine twice weekly as a ...... ith carcinoma: a phase I study

@en

type

label

Gemcitabine twice weekly as a ...... ith carcinoma: a phase I study

@ast

Gemcitabine twice weekly as a ...... ith carcinoma: a phase I study

@en

prefLabel

Gemcitabine twice weekly as a ...... ith carcinoma: a phase I study

@ast

Gemcitabine twice weekly as a ...... ith carcinoma: a phase I study

@en

P1433

Q33365043-E8336150-0852-4D0B-A363-131C21A7D99F

P1476

Q33365043-B765E3D5-5ABD-41DD-BB47-C3443171E6D6

P2093

Q33365043-0A39F3AC-52D3-4C50-90BC-8A0FB3F30E93

Q33365043-3194FF21-BECC-4FCA-941A-0923005E95F0

Q33365043-9B3D1908-4D40-4D6D-A9CC-95FA8908A279

Q33365043-A7490E36-8BEC-4877-8729-F8CE5993E988

Q33365043-B9BB6C6D-C503-41BE-9900-98554EC61E20

Q33365043-FC759F8B-6382-4766-A6EE-09C31C173A81

P2860

Q33365043-0FAAC040-B73F-4B54-ADB8-CD66627C0015

Q33365043-2DFA77C7-4AEF-485F-81BC-5DC4AD27BC7C

Q33365043-3B60CD7C-7248-4FBE-A335-FD78ADB87B69

Q33365043-71186040-BB5B-47F9-9437-F3EC10003718

Q33365043-77EEF36D-180F-406A-987E-52E92BF07528

Q33365043-7C76D0F9-5D1C-4B52-9D9A-32D1676FBA13

Q33365043-86249F72-08BA-497F-8D86-FFBD464752C9

Q33365043-8AEA54B7-D272-4275-92AA-82B66C20852D

Q33365043-9F149A60-7491-4DBF-8DC0-3EB8820AADD9

Q33365043-B155981F-9155-4834-95CD-946E35C795EE

P2888

Q33365043-213F9B42-6982-4060-A7F4-37D57B1F6BB0

P304

Q33365043-003AD874-AAEB-4788-B5A3-8C5BB38B2064

P31

Q33365043-728AD130-DC73-495F-89F6-842218B4E9EE

P356

Q33365043-ED653C7C-7D82-4E6B-9C5F-F572FED78224

P407

Q33365043-A522DF93-A523-4823-94C7-7F107CABA922

P433

Q33365043-13ECD08D-FD72-42D7-8353-0A5BF5C7BBF6

P478

Q33365043-9EB9042C-A72B-4540-A282-F322CE9FC07A

P577

Q33365043-A7CCD7F7-BE11-4D35-91D4-D64DE224B865

P5875

Q33365043-CDE60D55-5C30-4C69-941C-1C7493EBAEDE

P6179

Q33365043-8505CC73-6F51-4533-9660-E2B9B66EC47A

P698

Q33365043-E8E4FAB5-CA4C-47F9-B83E-F78DABE4D4BE

P932

Q33365043-3B7181E9-3E06-4BAC-9B66-635953DDF8A5

P356

P1433

British Journal of Cancer

P1476

Gemcitabine twice weekly as a ...... ith carcinoma: a phase I study

@en

P2093

A Maraveyas

http://www.w3.org/2001/XMLSchema#string

A-H Abdel-Hamid

http://www.w3.org/2001/XMLSchema#string

J Sgouros

http://www.w3.org/2001/XMLSchema#string

M Holmes

http://www.w3.org/2001/XMLSchema#string

M Lind

http://www.w3.org/2001/XMLSchema#string

S Upadhyay

http://www.w3.org/2001/XMLSchema#string

P2860

“Mini-mental state”

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study.

The role of apoptosis in 2',2'-difluoro-2'-deoxycytidine (gemcitabine)-mediated radiosensitization.

Identification of prognostic factors in patients with brain metastases: a review of 1292 patients.

The role of chemotherapy in brain metastases.

Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer.

Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study.

Gemcitabine: once-weekly schedule active and better tolerated than twice-weekly schedule.

Recent advances in the use of radiosensitizing nucleosides.

P2888

P304

815-819

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6602444

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

92

http://www.w3.org/2001/XMLSchema#string

P577

2005-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8019368

http://www.w3.org/2001/XMLSchema#string

P6179

1019919024

http://www.w3.org/2001/XMLSchema#string

P698

15714201

http://www.w3.org/2001/XMLSchema#string

P932

2361913

http://www.w3.org/2001/XMLSchema#string